FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: US Approves Sale of Nvidia's H200 Chips to China, But Zero Deliveries Made

By

Despite U.S. clearance for 10 Chinese companies, including Alibaba Group (HKG:9988), Tencent Holdings (HKG:0700) and ByteDance to buy Nvidia H200 chips, zero deliveries have been made to date, Reuters reported Thursday. citing three people familiar with the matter.

While the U.S. Commerce Department approved sales of up to 75,000 units per company, Beijing has reportedly told local companies to stall purchases.

Other companies that secured licenses to buy Nvidia chips include JD.com (HKG:9618), Lenovo (HKG:0992) and Hon Hai Precision Industry (TPE:2317) or Foxconn, the report said.

Nvidia CEO Jensen Huang expects U.S. President Donald Trump and Chinese President Xi Jinping to build on their good relationship during the US-China summit to improve ties, Huang told Chinese state broadcaster CCTV on Thursday.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Alibaba Health Seeks 10 Billion Yuan Share Premium Cut to Support Dividends; Shares Fall 7%

Alibaba Health Information Technology (HKG:0241) proposed a 10 billion yuan reduction in its share premium account to facilitate dividend distributions, according to a Thursday Hong Kong bourse filing.Shares of the digital health service provider fell 7% in late morning trade on Friday.The company said the proposed reduction would transfer the amount from its share premium account to contributed surplus, enabling payment of a final dividend and a special dividend for the year ended March 31.Alibaba Health proposed a final dividend of 0.0595 yuan per share and a special dividend of 0.1352 yuan per share.The company said the proposal was necessary because it had insufficient contributed surplus available for distribution.Alibaba Health's share premium account stood at about 51.7 billion yuan as of March 31, the filing showed.

$HKG:0241
Asia

Prestige Biologics Secures KRW2.4 Billion Contract Manufacturing Agreement for APIs

Prestige Biologics (KOSDAQ:334970) secured a contract manufacturing agreement for active pharmaceutical ingredients (APIs) following a technology transfer from an undisclosed client, according to a Friday filing with the Korea Exchange.The deal, valued at 2.40 billion won, is valid till March 31, 2027.Shares of Prestige Biologics fell nearly 2% in recent trade.

$KOSDAQ:334970
Asia

Thai Beverage's Attributable Profit Up 9% in Fiscal Q2

Thai Beverage's (SGX:Y92) attributable profit to owners rose 9% during the fiscal second quarter ended March 31 to 7.37 billion baht from 6.74 billion baht a year earlier, according to a Thursday filing with the Singapore Exchange.Shares of the beverage producer were up over 1% in Friday trading.Earnings per share came in at 0.29 baht compared with 0.27 baht in the year-ago period.Revenue from sale of goods inched up 1% year over year to 86.5 billion baht from 85.4 billion baht.The board approved an interim dividend of 0.15 baht per share for the period, unchanged from a year earlier. The dividend will be paid on June 12.

$SGX:Y92